Bruce Wendel
Direttore/Membro del Consiglio presso GT BIOPHARMA, INC.
Patrimonio netto: 44 081 $ in data 31/05/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Simon Geoffrey Best | M | 67 |
Liminal BioSciences Ltd.
Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 10 anni |
Pierre Laurin | M | 63 |
Liminal BioSciences Ltd.
Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 30 anni |
Patrick Soon-Shiong | M | 71 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.
Abraxis Health, Inc.
Abraxis Health, Inc. BiotechnologyHealth Technology Abraxis Health is establishing as a fully-integrated, next-generation, evidence-based, and personalized healthcare company. It plans to develop a proprietary model for the delivery of healthcare. Abraxis Health is designing and acquiring the necessary infrastructure and plans to acquire and internally develop the hardware and software modules to organize and integrate the data streams that form the foundation of an interactive database. The firm will develop, test, and validate diagnostics and drugs to target pre-selected patients based on molecular profiles that predict drug response to particular therapeutics. | 4 anni |
Michael Breen | M | 61 | 3 anni | |
Daniel Calkins | M | 37 | 6 anni | |
Ken Galbraith | M | 61 |
Liminal BioSciences Ltd.
Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 8 anni |
Brian Stuglik | M | 64 | 7 anni | |
David Jeans | M | 74 |
Liminal BioSciences Ltd.
Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 8 anni |
Edward C. Geehr | M | 75 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.
Abraxis Health, Inc.
Abraxis Health, Inc. BiotechnologyHealth Technology Abraxis Health is establishing as a fully-integrated, next-generation, evidence-based, and personalized healthcare company. It plans to develop a proprietary model for the delivery of healthcare. Abraxis Health is designing and acquiring the necessary infrastructure and plans to acquire and internally develop the hardware and software modules to organize and integrate the data streams that form the foundation of an interactive database. The firm will develop, test, and validate diagnostics and drugs to target pre-selected patients based on molecular profiles that predict drug response to particular therapeutics. | 2 anni |
Kurt Stefan Victor Clulow | M | 53 |
Liminal BioSciences Ltd.
Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 10 anni |
John Edward Moran | M | 79 |
Liminal BioSciences Ltd.
Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 12 anni |
Gary Bridger | M | 61 | 5 anni | |
Neil Klompas | M | 52 | 5 anni | |
John Johnson | M | 66 | 4 anni | |
Rajesh Shrotriya | M | 79 | 3 anni | |
Wayne A. Davey | M | - |
Abraxis Health, Inc.
Abraxis Health, Inc. BiotechnologyHealth Technology Abraxis Health is establishing as a fully-integrated, next-generation, evidence-based, and personalized healthcare company. It plans to develop a proprietary model for the delivery of healthcare. Abraxis Health is designing and acquiring the necessary infrastructure and plans to acquire and internally develop the hardware and software modules to organize and integrate the data streams that form the foundation of an interactive database. The firm will develop, test, and validate diagnostics and drugs to target pre-selected patients based on molecular profiles that predict drug response to particular therapeutics.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | - |
Eric Rowinsky | M | 67 | 7 anni | |
Timothy Steven Wach | M | 63 | 5 anni | |
Sandra Leung | F | 63 | 32 anni | |
Charles Casamento | M | 78 | 1 anni | |
Patrick Sartore | M | 49 |
Liminal BioSciences Ltd.
Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 9 anni |
Shawn Lu | M | 56 |
Hepalink USA, Inc.
Hepalink USA, Inc. Pharmaceuticals: MajorHealth Technology Hepalink USA, Inc. develops macromolecule biopharmaceutical products. The company offers scientific protein laboratories and active pharmaceutical ingredients. The company was founded in 1998 and is headquartered in Oak Brook, IL. | 10 anni |
Hagop Youssoufian | M | 67 | 7 anni | |
Jeffrey Miller | M | - | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Anthony Cataldo | M | 73 | 12 anni | |
Giovanni Caforio | M | 59 | 24 anni | |
Lamberto Andreotti | M | 73 | 19 anni | |
Robert M. Forrester | M | 60 | 8 anni | |
Gregory Berk | M | 66 | 4 anni | |
Peter R. Dolan | M | 68 | 18 anni | |
Jeff Yordon | M | 75 |
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL. | 10 anni |
Charles A. Heimbold | M | - | 20 anni | |
Joseph Chiapponi | M | 55 | 6 anni | |
Gavin Choy | M | - | - | |
Lonnie Moulder | M | 66 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 1 anni |
Leonard Shapiro | M | 96 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL.
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL | 9 anni |
Robert Mills | M | 71 |
Scientific Protein Laboratories LLC
Scientific Protein Laboratories LLC Pharmaceuticals: MajorHealth Technology Scientific Protein Laboratories LLC supplies pharmaceutical ingredients. It specializes in cGMP biopharmaceutical manufacturing and commercial supplies. The firm serves the pharmaceutical, veterinary, and food industries. It offers fermentation, natural product extractions, heparin derivatives, and recovery and purification. The company founded in 1976 and is headquartered in Waunakee, WI. | 3 anni |
G. Anthony | M | 68 | 9 anni | |
Nicole S. Williams | F | 79 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL. | 4 anni |
Michael J. Brunelle | M | 65 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 anni |
Jean-Francois Gimonet | M | - |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 3 anni |
Mitchall G. Clark | M | 63 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 anni |
Alison Lawton | F | 62 | 8 anni | |
Lisa Gopalakrishnan | F | 62 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 2 anni |
Diane L. Liguori | F | - | 1 anni | |
José Iglesias | M | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 anni |
Alan Urban | M | 55 | 1 anni | |
Frédéric Dumais | M | - | - | |
John E. Elicker | M | 64 | 20 anni | |
Steven B. Ratoff | M | 81 | 16 anni | |
Paul Mesburis | M | 54 | 10 anni | |
Fouad Namouni | M | 55 | 21 anni | |
Peter A. Pellegrino | M | 49 | 1 anni | |
John Doyle | M | 46 | 2 anni | |
Sean Flynn | M | 50 | 1 anni | |
Jason Haddock | M | 54 | 14 anni | |
Andrew Bishop | M | 58 | - | |
Murielle Lortie | F | 54 | 3 anni | |
Brian Sullivan | M | - | 9 anni | |
V. Dat Nguyen | M | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 anni |
Louise Paradis | F | - | 2 anni | |
Louise Ménard | F | 75 | 10 anni | |
Lyndal Walker | F | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 anni |
Robert H. Murdock | M | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 anni |
Joseph Hogan | M | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 anni |
Brian Daniels | M | 65 | 14 anni | |
Nicholas Everett | M | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 anni |
Nancy Orr | F | 73 | 8 anni | |
Gerald Bruce | M | 68 | 8 anni | |
Lewis B. Campbell | M | 77 | 18 anni | |
Kirk Calhoun | M | 80 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL. | 3 anni |
Harrison Bains | M | 80 | 16 anni | |
Charles Sigal | M | 72 | 16 anni | |
Anthony Hooper | M | 69 | 15 anni | |
Lawrence Hamilton | M | 66 | 8 anni | |
Michael Handelman | M | 65 | 1 anni | |
Timothy Meeker | M | 77 | 13 anni | |
Jeffrey Steven Silverman | M | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 1 anni |
Barry J. Wolfenson | M | 57 | 23 anni | |
S. Phanstiel | F | 65 | 6 anni | |
Gina Consylman | F | 52 | 3 anni | |
Priya Jambhekar | F | - | 3 anni | |
Laurie Glimcher | M | 72 | 20 anni | |
Leif Valdemar Johansson | M | 73 | 13 anni | |
Stephen D. Nimer | M | 70 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL. | 4 anni |
Joseph Squicciarino | M | 67 | 22 anni | |
Manu Ohri | M | 68 | 2 anni | |
Alan L. Heller | M | 70 |
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL. | 1 anni |
Paul Friedman | M | 81 | 3 anni | |
Robert Lacroix | M | 78 | 14 anni | |
Roger A. Perrault | M | 87 | 3 anni | |
David Chen | M | 76 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL. | 4 anni |
Raymond M. Hakim | M | 79 | 4 anni | |
Madelyn Zeylikman | F | - | - | |
Frank Perier | M | 64 | 9 anni | |
William R. Miller | M | 95 | 27 anni | |
Mitchell P. Cybulski | M | 77 | 6 anni | |
Lynn H. Clark | F | 66 | 8 anni | |
Ronald J. Prentki | M | 66 | 5 anni | |
William P. Keane | M | 68 | 1 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 78 | 78.00% |
Canada | 22 | 22.00% |
Regno Unito | 7 | 7.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Bruce Wendel
- Contatti personali